Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Therapy”

1,422 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,422 results

Early research (Phase 1)Ended earlyNCT03471351
What this trial is testing

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Who this might be right for
Classical Hodgkin Lymphoma
Rhizen Pharmaceuticals SA 2
Large-scale testing (Phase 3)Study completedNCT03976323
What this trial is testing

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Who this might be right for
Carcinoma, Nonsquamous Non-small-cell Lung
Merck Sharp & Dohme LLC 1,003
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT04165070
What this trial is testing

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)UnknownNCT05163483
What this trial is testing

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Who this might be right for
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Ruihua Xu 87
Testing effectiveness (Phase 2)UnknownNCT05392686
What this trial is testing

PD1 and PARP for Maintenance Therapy in NSLLC

Who this might be right for
Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 52
Early research (Phase 1)Active Not RecruitingNCT05334329
What this trial is testing

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+8 more
University of California, Irvine 6
Early research (Phase 1)Looking for participantsNCT06439836
What this trial is testing

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Who this might be right for
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI) 27
Large-scale testing (Phase 3)Active Not RecruitingNCT04956692
What this trial is testing

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Who this might be right for
Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 531
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07157306
What this trial is testing

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 35
Not applicableLooking for participantsNCT05717738
What this trial is testing

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Tongji Hospital 300
Not applicableNot Yet RecruitingNCT06682247
What this trial is testing

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Feng Wang 200
Large-scale testing (Phase 3)Looking for participantsNCT04453826
What this trial is testing

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal CancerChemotherapyRadiotherapy+1 more
Sun Yat-sen University 388
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 1,397
Large-scale testing (Phase 3)UnknownNCT04167293
What this trial is testing

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)

Who this might be right for
Hepatocellular Carcinoma
Mian XI 116
Post-approval studies (Phase 4)Looking for participantsNCT06311942
What this trial is testing

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Who this might be right for
HCC
Chen Xiaoping 300
Early research (Phase 1)UnknownNCT05019534
What this trial is testing

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E-mutated /MSS Metastatic Colorectal CancerVemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
West China Hospital 12
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 625
Testing effectiveness (Phase 2)UnknownNCT05023109
What this trial is testing

GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Who this might be right for
Biliary Tract Carcinoma
Shanghai Zhongshan Hospital 45
Post-approval studies (Phase 4)Looking for participantsNCT06597227
What this trial is testing

Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy

Who this might be right for
Locally Advanced Gastric Cancer
Guihua Wang 404
Load More Results